Advertisement
UK markets open in 5 hours 57 minutes
  • NIKKEI 225

    37,326.76
    -752.94 (-1.98%)
     
  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     
  • CRUDE OIL

    82.60
    -0.13 (-0.16%)
     
  • GOLD FUTURES

    2,392.50
    -5.50 (-0.23%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • Bitcoin GBP

    50,476.63
    +949.40 (+1.92%)
     
  • CMC Crypto 200

    1,303.24
    +417.71 (+46.74%)
     
  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     
  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     

Analyst Ratings for Nektar Therapeutics and Peers in March 2018

Analyst Ratings for Nektar Therapeutics and Peers in March 2018

Why Are Investors Excited about Nektar Therapeutics in 2018? Nektar Therapeutics (NKTR) is a biopharmaceutical company with investigational drug candidates for the treatment of cancer, autoimmune disease, and chronic pain. Of the nine analysts covering Nektar Therapeutics in March 2018, four of them have given the stock a “strong buy” rating.